With respect to the biological nature of HER2, the frequency of HER2 heterogeneity differs between HER2 positive GC and BC patients, being 45%–79% [25–28] and 11%–40% [8, 9, 29–33], respectively. This evidence concerns the gene ERBB2 and breast cancer.